Skip to content
Trial Agents

MLL Dx

MLL Dx is recorded as a service provider in 18 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

18distinct trials
10recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 18 of 18 trials · Latest update first

A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end

A Phase 3, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end
Operational learnings available1 trial-level finding · Read insights
  • EEA countries enrolled 148 of 201 participants, with the largest country enrollment in Italy (59 participants), followed by France (27) and Spain (25).

These findings describe the trial, not the service provider’s performance or responsibility.

A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of RVU120 in Combination with Venetoclax in Participants with Acute Myeloid Leukemia Who Failed Prior Therapy with Venetoclax and a Hypomethylating Agent (RIVER-81)

Sponsor Ryvu Therapeutics S.A.

Start (EU)
Latest update
Estimated end
Not reported

A Phase 3, Open-Label, Randomized Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituximab Retreatment) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both BTK and BCL2 Inhibitors

Sponsor BeOne Medicines AG

Start (EU)
Latest update
Estimated end

A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end

A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy ALIDHE

Sponsor Servier Affaires Medicales

Start (EU)
Latest update
Estimated end

A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions.

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE 536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-stimulating Agent (ESA)-naive Participants who are Non-transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end

A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

Sponsor Celgene Corp.

Start (EU)
Latest update
Estimated end

Questions about this trial experience

What services are recorded for MLL Dx?

The 2026-10-09 snapshot links MLL Dx to 18 distinct CTIS trials. Recorded services include Laboratory services, Biomarker analysis and Bone Marrow analysis, Analysis of exploratory endpoints, Short-term biosample storage, Biomarkers - genetics/genomics, FISH analyses, among 10 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for MLL Dx?

The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to MLL Dx conducted?

The linked trials record locations in 17 countries, including Italy, Spain, Poland, France, Czechia. These are trial locations, not confirmed office locations or countries where MLL Dx delivered services.

What can this page tell me about MLL Dx's trial experience?

Browse 18 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under MLL Dx. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • MLL Dx GmbH

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.

By entering your email, you agree to receive emails from Trial Agents. You can unsubscribe anytime.